Clinical Trial

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today…

12 months ago

H1 Welcomes Former FDA Commissioner to Board of Directors, Acquires Ribbon Health, and Unveils 2025 Product Roadmap

Doubles down on its commitment to connecting the world with the right doctors and advancing healthcare innovation and inclusionNEW YORK,…

12 months ago

NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year

Revenues in 4Q24 increased approximately 50% versus 4Q23Cash balance as of 12/31/24 was approximately $3.7 million CARMEL, Ind., Jan. 08,…

12 months ago

Quanta Announces IND Clearance by U.S. FDA for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates

– IND for QTX3544 is third for Quanta within one year – – Initiated combination portion of Phase 1 clinical…

12 months ago

Foresight Diagnostics Provides 2025 Outlook and 2024 Year in Review

- Achieved 100% revenue growth versus prior year – - Received Investigational Device Exemption approval from the FDA for the…

12 months ago

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicineWill provide key regulatory…

12 months ago

SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer

DENVER, Jan. 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary…

12 months ago

Safety Shot to Acquire Yerbaé Brands Corp., adding approximately $12 Million to Annual Revenue and Creating a Potential Force in Wellness and Functional Beverages

Yerbaé is a scalable, growth-oriented complementary brand with a large and growing addressable marketYerbaé creates clean, simple, and delicious plant-based…

12 months ago

SELLAS Announces Key Business Objectives for 2025

- Independent Data Monitoring Committee to Perform Interim Analysis of Phase 3 REGAL Study in January 2025 - - SLS009:…

12 months ago

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

Case reports published in medical literature suggest that tafenoquine combined with standard-of-care treatment exhibits a high cure rate in immunosuppressed…

12 months ago